Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.

Hypoplastic Left Heart Syndrome Clinical Trial

— TEMPO  

Official title:

Treatment With Endothelin Antagonist to Tcpc Patients; a Multicenter, Randomized, Prospective Study Measuring Maximal O2 Uptake in Ergometer Bicycle Test

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01292551
• Other study ID #: TEMPO study
• Secondary ID: 2010-022389-28
• Status: Completed
• Phase: Phase 2
• First received: February 8, 2011
• Last updated: April 18, 2013
• Start date: February 2011
• Est. completion date: March 2013

Study information

• Verified date: April 2013
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Danish Dataprotection AgencyDenmark: Danish Medicines AgencyDenmark: Ethics CommitteeDenmark: GCP units Copenhagen and Aarhus
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether Bosentan is an effective and safe treatment to adolescent and adult (15 years and older) patients, born with one ventricle of the heart instead of two (single ventricle physiology) and who have undergone TCPC as a palliative surgical treatment. The aim of the TCPC operation is to use the one functioning ventricle to pump the blood flow to the body, while the blood to the lungs is received directly from the caval veins, and is thus a passive flow, without the aid of a ventricle to actively pump the blood through the pulmonary circulation. The resistance in the pulmonary circulation is therefore critical to these patients. These patients have markedly lower work capacity in bicycle test than the general public. Furthermore they have a high risk of developing complications e.g. loss of protein from the intestines.

Bosentan is a medication that lowers the resistance in the pulmonary circulation. It is routinely used for patients with pulmonary hypertension. Some studies have shown that drugs that lower the pulmonary resistance can increase exercise capacity significantly in patients with single ventricle physiology.

In this study 80 patients will receive either placebo or Bosentan for 14 weeks. Before and after the treatment, bicycle test along with blood samples, stool samples and quality of life interviews will be performed. Every four weeks during the study blood samples, physical exam and interviews will be performed to ensure the safety of the treatment.

The investigators expect to find a significant increase in work capacity after 14 weeks in the treatment group compared with the placebo group.

Moreover the investigators hope to find a decrease in intestinal protein loss and an improved quality of life.

Description:

In the statistical analysis the investigators wish to analyse interactions between the primary endpoint and predefined subgroups in order to distinguish responders from non-responders to the treatment. The predefined subgroups are:

NT-proBNP > 100 (yes/no) Ventricular anatomy (RV/LV) CT-proEndothelin-1. In the latter, the investigators do not wish to predefine a specific value, due to limited experience with this analysis. We wish to use the data from the study to find a cut-off value, that is able to predict positive response to treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: March 2013
• Est. primary completion date: March 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• TCPC operated

• Age > 15 years old

• Clinical stability > 3 months, evaluated by investigator from clinical record

• For women: Negative s-hCG and use of contraception

Exclusion Criteria:

• Severe heart failure (NYHA-class IV)

• Oxygen saturation < 85 % at rest

• Pre-existing liver condition (transaminases 2x > reference)

• Renal failure (creatinin > 150 mmol/l)

• Obstruction of TCPC circulation

• History of work induced severe arrhythmia

• Systolic blood pressure below 80% of reference (BT < 88 mmHg)

• Use of any of following drugs: Fluconazol, Ketoconazole, CiclosporinA, Lopinavir, Ritonavir, Rifampicin, Carbamazepin and Phenytoin

• Significant extra-cardiac condition e.g. neurological impairment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Congenital Abnormalities
• Heart Defects, Congenital
• Hypoplastic Left Heart Syndrome
• Other Specified Congenital Anomalies of Heart
• Tricuspid Atresia

Intervention

Drug:
• Bosentan
tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks
• Placebo
Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks

Locations

Country	Name	City	State
Denmark	Aarhus University Hospital	Aarhus
Denmark	Rigshospitalet	Copenhagen
Sweden	Lund University Hospital	Lund
Sweden	Karolinska Institutet	Stockholm

Sponsors (4)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark	Aarhus University Hospital, Actelion, Bispebjerg Hospital

Countries where clinical trial is conducted

Denmark,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in VO2max at 14 weeks	Maximal O2 uptake in ml/min/kg in ergometer bicycle test	Baseline and 14 weeks	No
Secondary	Change from baseline in blood samples at 14 weeks	blood samples measured: plasma CT pro endothelin-1, IgG, IgA, NT pro BNP, albumin, free protein	Baseline and 14 weeks	No
Secondary	Change from baseline in SF36 questionnaire score at 14 weeks	SF36 quality of life interview	Baseline and 14 weeks	No
Secondary	Change from baseline in feces alfa 1 antitrypsin at 14 weeks	Fecal alfa 1 antitrypsin in mg/g	Baseline and 14 weeks	No
Secondary	Number of participants with adverse events	general interview on adverse effects, and questions with special focus on typical adverse effects in Bosentan	2, 6, 10 and 14 weeks after start of treatment	Yes
Secondary	Change from baseline in vital signs	Systemic bloodpressure in mmHg, Pulse in min-1, Oxygen saturation in percent	Baseline, 2, 6, 10 and 14 weeks	Yes
Secondary	Change from baseline in control blood samples	Liver and renal biomarkers, Hb, PCV, trc and hCG for women	Baseline, 2, 6, 10 and 14 weeks	Yes
Secondary	Change from baseline in cardiac output/pulmonary blood flow	CO measured by Stringer Wassermann method during ergometer bicycle test	Baseline and 14 weeks	No